JP2009539802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539802A5 JP2009539802A5 JP2009513691A JP2009513691A JP2009539802A5 JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5 JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009513691 A JP2009513691 A JP 2009513691A JP 2009539802 A5 JP2009539802 A5 JP 2009539802A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- mass
- pharmaceutical composition
- mpa
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 3
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims 3
- 229960002978 fesoterodine Drugs 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- 239000000811 xylitol Substances 0.000 claims 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 3
- 229960002675 xylitol Drugs 0.000 claims 3
- 235000010447 xylitol Nutrition 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 208000020629 overactive bladder Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 206010036018 Pollakiuria Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06011941.9 | 2006-06-09 | ||
| EP06011942 | 2006-06-09 | ||
| EP06011943.5 | 2006-06-09 | ||
| EP06011942.7 | 2006-06-09 | ||
| EP06011943 | 2006-06-09 | ||
| EP06011941 | 2006-06-09 | ||
| PCT/EP2007/055582 WO2007141298A1 (en) | 2006-06-09 | 2007-06-06 | Stabilized pharmaceutical compositions comprising fesoterodine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011041842A Division JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539802A JP2009539802A (ja) | 2009-11-19 |
| JP2009539802A5 true JP2009539802A5 (enExample) | 2011-05-06 |
| JP4743321B2 JP4743321B2 (ja) | 2011-08-10 |
Family
ID=38521333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513691A Active JP4743321B2 (ja) | 2006-06-09 | 2007-06-06 | フェソテロジンを含む安定した医薬組成物 |
| JP2011041842A Active JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011041842A Active JP4781489B2 (ja) | 2006-06-09 | 2011-02-28 | フェソテロジンを含む安定した医薬組成物 |
Country Status (37)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| IT1392082B1 (it) * | 2008-12-10 | 2012-02-09 | Chemi Spa | Nuove forme solide della fesoterodina fumarato |
| US9085507B2 (en) | 2009-05-11 | 2015-07-21 | Ratiopharm Gmbh | Desfesoterodine in the form of a tartaric acid salt |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20130172411A1 (en) * | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| US20140199401A1 (en) * | 2011-07-04 | 2014-07-17 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of fesoterodine |
| EP2780317A2 (en) * | 2012-05-18 | 2014-09-24 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| ES2674811T3 (es) * | 2012-07-02 | 2018-07-04 | Hetero Research Foundation | Composiciones estables de fesoterodina |
| SG11201503440UA (en) | 2012-11-02 | 2015-06-29 | Heart Care Western Australia Pty Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| BR112015026418B1 (pt) | 2013-04-16 | 2022-10-04 | Murray And Poole Enterprises Limited | Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina |
| HUE054663T2 (hu) * | 2013-04-16 | 2021-09-28 | Murray & Poole Entpr Ltd | A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| CN105687154A (zh) * | 2014-11-27 | 2016-06-22 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| WO2019011393A1 (en) | 2017-07-12 | 2019-01-17 | Rontis Hellas S.A. | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF |
| TR201721437A2 (tr) * | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
| WO2019132832A1 (en) * | 2017-12-25 | 2019-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet compositions of fesoterodine fumarate |
| KR102018495B1 (ko) * | 2018-03-13 | 2019-09-05 | 충북대학교 산학협력단 | 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법 |
| CA3094551C (en) | 2018-04-26 | 2024-01-02 | Rontis Hellas S.A. | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof |
| CN110151720B (zh) * | 2019-05-09 | 2019-12-17 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| JP2023531802A (ja) * | 2020-06-30 | 2023-07-25 | インブリア ファーマシューティカルズ， インコーポレイテッド | トリメタジジンの改変形態の調節放出製剤 |
| WO2023145486A1 (ja) * | 2022-01-28 | 2023-08-03 | 沢井製薬株式会社 | フェソテロジンフマル酸塩含有製剤の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU757002B2 (en) * | 1998-03-03 | 2003-01-30 | Eli Lilly And Company | Pharmaceutical compositions containing the phospholipase inhibitor sodium ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1- phenylmethyl)-1H-indol-4-YL)oxy)acetate |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19955190A1 (de) * | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| DE10224107A1 (de) * | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
-
2007
- 2007-06-06 PL PL07729956T patent/PL2029134T3/pl unknown
- 2007-06-06 HR HR20110776T patent/HRP20110776T1/hr unknown
- 2007-06-06 WO PCT/EP2007/055582 patent/WO2007141298A1/en not_active Ceased
- 2007-06-06 TW TW102118368A patent/TWI520735B/zh not_active IP Right Cessation
- 2007-06-06 PE PE2011001996A patent/PE20120476A1/es not_active Application Discontinuation
- 2007-06-06 AT AT07729956T patent/ATE517619T1/de active
- 2007-06-06 PT PT07729956T patent/PT2029134E/pt unknown
- 2007-06-06 MX MX2008015736A patent/MX2008015736A/es active IP Right Grant
- 2007-06-06 AU AU2007255408A patent/AU2007255408B2/en not_active Ceased
- 2007-06-06 AP AP2008004673A patent/AP2416A/xx active
- 2007-06-06 UY UY30394A patent/UY30394A1/es active IP Right Grant
- 2007-06-06 JP JP2009513691A patent/JP4743321B2/ja active Active
- 2007-06-06 MY MYPI20084409A patent/MY146574A/en unknown
- 2007-06-06 SI SI200730758T patent/SI2029134T1/sl unknown
- 2007-06-06 NZ NZ572616A patent/NZ572616A/en not_active IP Right Cessation
- 2007-06-06 ES ES07729956T patent/ES2370943T3/es active Active
- 2007-06-06 PE PE2007000695A patent/PE20080331A1/es active IP Right Grant
- 2007-06-06 DK DK07729956.8T patent/DK2029134T3/da active
- 2007-06-06 KR KR1020087027920A patent/KR101316773B1/ko active Active
- 2007-06-06 TW TW096120242A patent/TWI397409B/zh not_active IP Right Cessation
- 2007-06-06 EA EA200802444A patent/EA015909B9/ru active Protection Beyond IP Right Term
- 2007-06-06 BR BRPI0712865-7A patent/BRPI0712865B1/pt not_active IP Right Cessation
- 2007-06-06 CA CA2652712A patent/CA2652712C/en active Active
- 2007-06-06 RS RS20110469A patent/RS51973B/sr unknown
- 2007-06-06 CN CN2007800212925A patent/CN101466371B/zh not_active Expired - Fee Related
- 2007-06-06 EP EP07729956A patent/EP2029134B1/en active Active
- 2007-06-08 NL NL2000690A patent/NL2000690C2/nl active Search and Examination
- 2007-06-08 AR ARP070102485A patent/AR061289A1/es not_active Application Discontinuation
-
2008
- 2008-07-21 ZA ZA200806411A patent/ZA200806411B/xx unknown
- 2008-12-01 NI NI200800318A patent/NI200800318A/es unknown
- 2008-12-04 GT GT200800276A patent/GT200800276A/es unknown
- 2008-12-04 IL IL195732A patent/IL195732A/en not_active IP Right Cessation
- 2008-12-05 TN TNP2008000505A patent/TNSN08505A1/fr unknown
- 2008-12-08 CU CU2008000235A patent/CU23850B1/es active IP Right Grant
- 2008-12-08 MA MA31460A patent/MA30504B1/fr unknown
- 2008-12-11 CR CR10494A patent/CR10494A/es unknown
- 2008-12-24 EC EC2008009010A patent/ECSP089010A/es unknown
-
2009
- 2009-01-09 NO NO20090141A patent/NO341980B1/no unknown
-
2011
- 2011-02-28 JP JP2011041842A patent/JP4781489B2/ja active Active
- 2011-10-17 CY CY20111100983T patent/CY1111934T1/el unknown
-
2012
- 2012-07-05 IL IL220800A patent/IL220800A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110776T1 (hr) | Stabilizirani farmaceutski sastavi koji sadrže fesoterodin | |
| JP2014167026A5 (enExample) | ||
| HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
| JP2016006108A5 (enExample) | ||
| CN101431990B (zh) | 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合 | |
| JP2017537954A5 (enExample) | ||
| HRP20170682T1 (hr) | Kruti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksokinolin-3-karboksamida | |
| JP2009537554A5 (enExample) | ||
| NZ586025A (en) | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate | |
| JP2011510024A5 (enExample) | ||
| JP2011503300A5 (enExample) | ||
| JP2012518656A5 (enExample) | ||
| TW201038300A (en) | Galenic formulations of organic compounds | |
| CN103919735B (zh) | 一种盐酸坦索罗辛缓释微丸及其制备方法 | |
| JP2022538911A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016172752A (ja) | 排尿頻度を減少させるための延長放出製剤およびその使用の方法 | |
| JP2017502948A (ja) | 新規な組成物 | |
| JPWO2021246388A5 (enExample) | ||
| JP2011140504A5 (enExample) | ||
| RU2018111690A (ru) | Пероральная лекарственная форма будесонида | |
| WO2008023390A3 (en) | Modified release pharmaceutical composition of bupropion hydrochloride | |
| HK1250628A1 (zh) | 用於遗尿的药物制剂及其使用方法 | |
| CN104800184B (zh) | 琥珀酸呋罗曲坦缓释剂片 | |
| JP2013032308A5 (enExample) |